Overview
Lobbying Costs
400,000€ - 499,999€
Financial year: Apr 2020 - Mar 2021
Lobbyists (Full time equivalent)
1.25 Fte (2)
Lobbyists with EP accreditation
2
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Astellas Pharma Europe Limited (APEL)
EU Transparency Register
726065718920-12 First registered on 24 Sep 2015
Goals / Remit
Providing high quality medicines in areas of high unmet medical need
Main EU files targeted
Intellectual Property Rights and incentives - including Orphan Medicinal Products, Paediatric medicines
Free Trade Agreements - EU/US, EU/UK,
EU Beating Cancer Plan,
EU Green Deal, Pharmaceuticals in the environment (PIE), the Circular Economy, Climate change, Energy taxes,
Industrial strategy,
Competition law,
Horizon Europe,
Innovative Medicines Initiative (IMI),
European Medicines Agency (EMA),
Committee of the Regions,
Clinical Trials Regulation,
Data Protection Regulation,
Digital health,
Community code related to medicinal products for human use in mainly countries that are part of the European Union.
Other policy areas of interest include Manufacturing, Health outcomes, Real world evidence, Pricing, reimbursement and market access to medicines, cancer, healthcare sustainability, patient advocacy group payments, transfers of value to healthcare professionals and healthcare organisations.Address
Head Office
Bourne Business Park 300 Dashwood Lang Road
Addlestone KT15 2NX
UNITED KINGDOMEU Office
Bourne Business Park 300 Dashwood Lang Road
Addlestone KT15 2NX
UNITED KINGDOMWebsite
-
People
Total lobbyists declared
2
Employment time Lobbyists 100% 1 25% 1 Lobbyists (Full time equivalent)
1.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
2 accreditations were / are live (in bold) for the selected state of 13 May 2022
Name Start date End Date Mélanie Yammine 14 Oct 2024 13 Oct 2025 Rachel DIXON 20 Sep 2023 14 Sep 2024 Melanie YAMMINE 20 Sep 2023 14 Sep 2024 Rachel DIXON 29 Mar 2022 29 Mar 2023 Melanie YAMMINE 29 Mar 2022 29 Mar 2023 Melanie YAMMINE 09 Nov 2018 09 Nov 2019 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
EFPIA
Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Apr 2020 - Mar 2021
Lobbying costs for closed financial year
400,000€ - 499,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount incisive health 100,000€ - 199,999€ Intermediaries for current year
Name incisive health Closed year Costs
400,000€ - 499,999€
Other financial info
We collaborate with Incisive Health to lead the Let's Talk Prostate Cancer campaign, advocating for a greater visibility of prostate cancer in EU public policies and debates.
We are a member of EFPIA and the EFPIA Oncology platform. -
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
We are a member of the European Federation of Pharmaceutical Industries and Associations and its Oncology platform. We are participating in events on industrial, health and life science policy.
We are meeting with policy makers in the EU institutions and engaging with other public policy stakeholders.
We are funding and participating in a campaign called Let's Talk Prostate Cancer.Other activities
None declared
Meetings
Meetings
None declared